Invention Grant
US08193328B2 Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
失效
鉴定丝氨酸蛋白酶抑制剂Kazal的调节剂及其作为抗癌和抗病毒剂的用途
- Patent Title: Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
- Patent Title (中): 鉴定丝氨酸蛋白酶抑制剂Kazal的调节剂及其作为抗癌和抗病毒剂的用途
-
Application No.: US12065840Application Date: 2006-09-07
-
Publication No.: US08193328B2Publication Date: 2012-06-05
- Inventor: Xuanyong Lu , Timothy Block
- Applicant: Xuanyong Lu , Timothy Block
- Applicant Address: US PA Philadelphia
- Assignee: Philadelphia Health & Education Corporation
- Current Assignee: Philadelphia Health & Education Corporation
- Current Assignee Address: US PA Philadelphia
- Agency: Woodcock Washburn, LLP
- International Application: PCT/US2006/034748 WO 20060907
- International Announcement: WO2007/030560 WO 20070315
- Main IPC: C12N15/15
- IPC: C12N15/15 ; C12N15/11 ; C12N15/113
Abstract:
This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).
Public/Granted literature
Information query
IPC分类:
